News | January 27, 2023
Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
Cell sorting technology supports researchers advancing new therapies
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Granules now have a total of 53 ANDA approvals from USFDA
Medical Tourism will boost India’s economy
Asthma patients are more likely to have an asthma attack during winter
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
Subscribe To Our Newsletter & Stay Updated
